{
    "symbol": "MEDS",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-27 21:30:05",
    "content": "  The company's annual report, which includes additional information regarding the company's results of operations for the year ended December 31, 2022, was filed with the SEC earlier today. For the 12 months of 2021, TRxADE Prime reported a negative gross margin of 12% compared to a positive 1% for the same period in 2022. Consolidated gross profit for the fiscal year of 2022 compared to 2021 improved $700,000, but remained consistent year-over-year at 48% as a percentage of revenue. Net loss for the year ended December 31, 2022, was $3.9 million loss or $0.41 loss per basic and diluted share outstanding compared to $5.3 million or $0.65 loss per basic and diluted share outstanding for the year ending December 31, 2021. For any of you who may have joined the call in progress, remember that the replay of this call and webcast will be available for the next 30 days on the company's website under the NASDAQ: MEDS link, and that more information regarding the financial information disclosed on this call and webcast, including a reconciliation of non-GAAP financial information can be found in our press release, which was filed after the close of market today."
}